MX2016007066A - Identification of predictive biomarkers associated with wnt pathway inhibitors. - Google Patents
Identification of predictive biomarkers associated with wnt pathway inhibitors.Info
- Publication number
- MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A
- Authority
- MX
- Mexico
- Prior art keywords
- wnt pathway
- identification
- pathway inhibitors
- biomarkers associated
- predictive biomarkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides biomarkers for identifying tumors likely to respond to treatment with Wnt pathway inhibitors. Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with a Wnt pathway inhibitor. Methods for treating a patient with cancer are provided, wherein the cancer is predicted to respond to a Wnt pathway inhibitor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361910663P | 2013-12-02 | 2013-12-02 | |
US201461975339P | 2014-04-04 | 2014-04-04 | |
PCT/US2014/068097 WO2015084808A1 (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016007066A true MX2016007066A (en) | 2016-09-08 |
Family
ID=53274023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007066A MX2016007066A (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3077546A4 (en) |
JP (1) | JP2017501137A (en) |
CN (1) | CN105829547A (en) |
AU (1) | AU2014357354A1 (en) |
CA (1) | CA2931975A1 (en) |
HK (1) | HK1223657A1 (en) |
MX (1) | MX2016007066A (en) |
TW (1) | TW201610168A (en) |
WO (1) | WO2015084808A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CA2899353A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US20180223372A1 (en) * | 2015-08-03 | 2018-08-09 | Oncomed Pharmaceutical, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
MX2018003179A (en) * | 2015-09-16 | 2018-08-21 | Tobira Therapeutics Inc | Cenicriviroc combination therapy for the treatment of fibrosis. |
KR20190085935A (en) * | 2016-10-26 | 2019-07-19 | 리프 테라퓨틱스 인코포레이티드 | Use of beta-catenin as a biomarker for the treatment of cancer using anti-DKK-1 antibodies |
CN106990245B (en) * | 2017-04-05 | 2018-07-31 | 东南大学 | Detect application of the reagent of PITX1 expression quantity in preparing gastric cancer prognosis evaluation reagent kit |
CN110835372B (en) * | 2019-11-06 | 2020-12-01 | 上海健康医学院 | Targeting Frizzled7 monoclonal antibody, and preparation method and application thereof |
CN111735949B (en) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a and CA125 combined as early ovarian cancer biomarker and kit |
CN115337400A (en) * | 2021-05-13 | 2022-11-15 | 中国科学院分子细胞科学卓越创新中心 | Reagent for diagnosing and treating tumor and its use |
CN113293212A (en) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | Primer probe for detecting amplification of neuroblastoma recurrence transfer gene FZD2 and application thereof |
WO2023113013A1 (en) * | 2021-12-17 | 2023-06-22 | 国立大学法人京都大学 | Method for selecting gene for use in estimation of possibility of onset of disease, and method for estimating possibility of onset of disease |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
EP1194549A2 (en) * | 1999-07-02 | 2002-04-10 | Chiron Corporation | Human genes and gene expression products |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
DK1355919T3 (en) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molecules with longer half-lives, compositions and uses thereof |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004032838A2 (en) * | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
AU2005279347A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
JP5129149B2 (en) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions and methods for treating and diagnosing cancer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
SG174101A1 (en) | 2006-09-08 | 2011-09-29 | Genentech Inc | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
MX2009003229A (en) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer. |
WO2008039071A2 (en) * | 2006-09-29 | 2008-04-03 | Agendia B.V. | High-throughput diagnostic testing using arrays |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
EP2287174B8 (en) | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
DK2331136T3 (en) * | 2008-09-26 | 2018-03-05 | Oncomed Pharm Inc | FRIZZLED BINDING AGENTS AND APPLICATIONS THEREOF |
US20100169025A1 (en) * | 2008-10-10 | 2010-07-01 | Arthur William T | Methods and gene expression signature for wnt/b-catenin signaling pathway |
US20120053079A1 (en) * | 2009-03-06 | 2012-03-01 | University Of South Alabama | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
CN102812044A (en) | 2010-01-12 | 2012-12-05 | 昂考梅德药品有限公司 | WNT-binding agents and uses thereof |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
-
2014
- 2014-12-02 MX MX2016007066A patent/MX2016007066A/en unknown
- 2014-12-02 TW TW103141799A patent/TW201610168A/en unknown
- 2014-12-02 AU AU2014357354A patent/AU2014357354A1/en not_active Abandoned
- 2014-12-02 JP JP2016535646A patent/JP2017501137A/en active Pending
- 2014-12-02 WO PCT/US2014/068097 patent/WO2015084808A1/en active Application Filing
- 2014-12-02 CA CA2931975A patent/CA2931975A1/en not_active Abandoned
- 2014-12-02 CN CN201480065718.7A patent/CN105829547A/en active Pending
- 2014-12-02 EP EP14867583.8A patent/EP3077546A4/en not_active Withdrawn
-
2016
- 2016-10-17 HK HK16111927.7A patent/HK1223657A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014357354A1 (en) | 2016-06-09 |
EP3077546A1 (en) | 2016-10-12 |
CN105829547A (en) | 2016-08-03 |
TW201610168A (en) | 2016-03-16 |
WO2015084808A4 (en) | 2015-08-13 |
HK1223657A1 (en) | 2017-08-04 |
WO2015084808A1 (en) | 2015-06-11 |
EP3077546A4 (en) | 2017-04-26 |
CA2931975A1 (en) | 2015-06-11 |
JP2017501137A (en) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016007066A (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors. | |
IL261353A (en) | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours | |
PH12017500293A1 (en) | Boronic acid derivatives | |
IL260400B (en) | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | |
HK1213189A1 (en) | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors | |
MX2017004043A (en) | Boronic acid derivatives. | |
MX2017004037A (en) | Boronic acid derivatives. | |
MX2017004046A (en) | Boronic acid derivatives. | |
EP3394032A4 (en) | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | |
MX2018006781A (en) | Mat2a inhibitors for treating mtap null cancer. | |
MX2015014660A (en) | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors. | |
EA201491699A1 (en) | CANCER TREATMENT WITH TOR KINASE INHIBITORS | |
EA201491701A1 (en) | CANCER TREATMENT WITH TOR KINASE INHIBITORS | |
MX2014011500A (en) | Diagnosis and treatments relating to her3 inhibitors. | |
MX2015011428A (en) | Methods of treating and preventing cancer drug resistance. | |
TN2019000212A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
MX2015007185A (en) | Use of eribulin in the treatment of breast cancer. | |
MY180834A (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
MX2015016305A (en) | Predictive biomarker for cancer therapy. | |
MA40636A (en) | Methods of detecting prostate cancer | |
MX2016009655A (en) | Novel methods for treating cancer. | |
JO3730B1 (en) | Use of pan FGFR inhibitors and method of identifying patients with cancer eligible for treatment with a pan FGFR inhibitor | |
IL249741A0 (en) | Identification of cancer stem cells markers and use of same for diagnosis and treatment | |
GB2480980A (en) | Methods for predicting cancer response to EGFR inhibitors |